secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2026-09-03T13:21:44+00:00
Accession:  0001599298-26-000076
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit partner Akeso reports positive OS for ivonescimab in HARMONi-2 vs pembrolizumab
--------------------------------------------------------------------------------

- Akeso's HARMONi-2: statistically significant OS improvement for ivonescimab vs pembrolizumab in PD-L1-positive advanced NSCLC.
- Primary PFS analysis earlier: HR 0.51 (95% CI 0.38-0.69; p<0.0001) by IRRC; OS data to be presented at upcoming medical conference.
- Ivonescimab was approved by China's NMPA in April 2025 based on HARMONi-2; Summit holds license rights in US/Europe where it remains investigational.
- Summit is conducting HARMONi-7 in PD-L1 high-expressing NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000076/0001599298-26-000076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000076/smmt-20260902.htm
  HTML page:      https://secwatch.observer/filing/0001599298-26-000076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer